Brwned
Have you ever been in love before?
- Joined
- Apr 18, 2008
- Messages
- 50,947
Can you please provide a source for your comments on the Chinese vaccine? I have a friend who has access to Sinopharms vaccine but is still deciding if he should sign up for the jab, would be useful to know some info.
Here's a recent article discussing it in Nikkei Asia (maybe a bit gleefully?) and here it is in the Washington Post a little earlier. They both relate to this journal in the Lancet about Sinovac rather than Sinopharm. From this journal comparing the phase I/II results of the main vaccines, Sinopharm did perform notably better than Sinovac in the phase II trials, but we don't know the phase III results yet. I wouldn't take a vaccine until they've released phase III and it has been assessed by experts. That's when they thoroughly assess its safety and its efficacy. What we know so far is it generates some immune response and it is safe enough to continue testing, like Sinovac, but we don't know how well it performs.
On Nov. 17, British medical journal The Lancet featured a study about the efficacy of Sinovac Biotech's vaccine candidate based on initial clinical trials. It found that the Chinese company's candidate generated lower levels of protective antibodies than those present in recovered coronavirus patients. The efficacy was determined to be moderate.
In contrast, the candidates from U.S.-based Pfizer and Moderna were found to be more than 90% effective, while the offering from Britain's AstraZeneca had an overall efficacy rate of 70%. Both American pharma companies used cutting-edge technology to develop their products.
Sinovac used an inactivated virus that does not induce illness to develop its candidate, a tried-and-true method long employed for fighting pathogens such as influenza. The report of moderate success therefore caused ripples because more solid results were expected.
The team in The Lancet study confirmed the presence of antibodies and found no safety problems, sufficient evidence to continue with clinical trials. Sinovac senior director Meng Weining told an online conference on Nov. 20 that final-phase trials were proceeding smoothly.
"I guess maybe next month we'll have data available," he said.
What Sinopharm are saying is particularly strange, assuming it's not being mischaracterised. They haven't released phase III results but they're happy to say it's safe because they've just done an uncontrolled trial on over a million people and...no problems so far? But then maybe there's been no problems because they're not actually following up to check? It's all a bit curious.
People lined up to receive inoculations Thursday at a Sinopharm research lab in Beijing, a program that has been expanded before the end of clinical trials.
Nearly 1 million people have received inoculations, the company said Nov. 18, up from 350,000 in September. Inoculations of individuals such as employees of state-owned companies have nearly tripled over the past two months.
Several such employees reported being inoculated in September but that Sinopharm made no attempt to contact them.
This raises questions about the effort being made to check on the health of people receiving a vaccine under development. Normally such contact would occur right after inoculation, as well as six months to a year later.
"After close to 1 million inoculations, there has not been a single adverse reaction," Sinopharm Chairman Liu Jingzhen said in a statement Nov. 18.